Safety and ef fi cacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer : a meta-analysis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

  2014influential reference
• Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

  2013cited by this paper
• Outcomes From IBD-Associated and Non-IBD-Associated Colorectal Cancer: A Surveillance Epidemiology and End Results Medicare Study

  2012cited by this paper
• Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy

  2012cited by this paper
• NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.

  2012cited by this paper
• Complications associated with erythropoietin‐stimulating agents in patients with metastatic breast cancer

  2011cited by this paper
• PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.

  2011cited by this paper
• PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosi

  2011cited by this paper
• PD07-06: Adjuvant Chemotherapy with or without Darbepoetin alpha in Node-Positive Breast Cancer: Survival and Quality of Life Analysis from the Prospective Randomized WSG ARA Plus Trial.

  2011influential reference
• Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial

  2010cited by this paper
• Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

  2010cited by this paper
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

  2010cited by this paper
• Adjuvant chemotherapy with or without darbepoetin in node-positive breast cancer: a safety analysis from the phase III ARA plus trial.

  2009cited by this paper
• Noninfectious complications of blood transfusion.

  2009cited by this paper
• Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

  2009cited by this paper
• Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

  2009cited by this paper
• Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

  2008cited by this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cited by this paper
• September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.

  2008cited by this paper
• Cancer-related anemia and recombinant human erythropoietin—an updated overview

  2006cited by this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2006influential reference
• Patient and caregiver time burden associated with anaemia treatment in different patient populations

  2006cited by this paper
• Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

  2005influential reference
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005influential reference
• Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

  2005influential reference
• The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

  2004cited by this paper
• Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy.

  2002cited by this paper
• Chemotherapy-induced anemia in adults: incidence and treatment.

  1999cited by this paper
• Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.

  1997cited by this paper

• The optimum hematocrit

  2016cites this paper
• Primum non nocere.

  2015cites this paper